{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T22:33:21Z","timestamp":1768862001356,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bulcan.2025.09.010","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:33:45Z","timestamp":1765802025000},"page":"5-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isatuximab, bortezomib, l\u00e9nalidomide et dexam\u00e9thasone\u00a0\u2013\u00a0my\u00e9lome multiple nouvellement diagnostiqu\u00e9 in\u00e9ligible \u00e0 la greffe"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4110-2052","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Pichon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Bobin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.bulcan.2025.09.010_bib0030","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.bulcan.2025.09.010_bib0035","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bulcan.2025.09.010_bib0040","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3\u00a0BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bulcan.2025.09.010_bib0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bulcan.2021.10.007","article-title":"Nouvelle AMM\u00a0: l\u2019idecabtagene vicleucel dans le my\u00e9lome multiple en rechute ou r\u00e9fractaire apr\u00e8s au moins trois lignes de traitements","volume":"109","author":"Croizier","year":"2022","journal-title":"Bull Cancer (Paris)"},{"issue":"10","key":"10.1016\/j.bulcan.2025.09.010_bib0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bulcan.2022.06.001","article-title":"Nouvelles AMMs\u00a0: ciltacabtagene autoleucel\u00a0\u2013\u00a0patients atteints d\u2019un my\u00e9lome multiple en rechute ou r\u00e9fractaire apr\u00e8s au moins trois lignes de traitements","volume":"109","author":"Chacon","year":"2022","journal-title":"Bull Cancer (Paris)"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125005144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125005144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:13:52Z","timestamp":1768814032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125005144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0007455125005144"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.09.010","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isatuximab, bortezomib, l\u00e9nalidomide et dexam\u00e9thasone\u00a0\u2013\u00a0my\u00e9lome multiple nouvellement diagnostiqu\u00e9 in\u00e9ligible \u00e0 la greffe","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}